Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the moment with its Prevnar franchise, Merck has multiple ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Selling, general and administrative expenses were $2.6 billion in the first quarter, Merck noted, an increase of 3% compared with the first quarter of 2024. The increase was primarily due to higher ...

Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks.

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...

The CDC’s ACIP updated guidance on pneumococcal vaccination, recommending a single dose of PCV for all adults aged 50 years and older.

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

Merck MRK reported first-quarter 2025 adjusted ... rose 7% to $228 million, while Pneumovax 23 (pneumococcal vaccine polyvalent) vaccine sales declined 30% to $41 million. Sales of the ...